- Previous Close
5.55 - Open
5.80 - Bid 6.05 x --
- Ask 6.40 x --
- Day's Range
5.80 - 6.50 - 52 Week Range
3.56 - 48.20 - Volume
11,813 - Avg. Volume
6,852 - Market Cap (intraday)
30.846M - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-1.89 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company's products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
www.respiratorius.comRecent News: RESP.ST
View MorePerformance Overview: RESP.ST
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RESP.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RESP.ST
View MoreValuation Measures
Market Cap
30.85M
Enterprise Value
30.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.02
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.96%
Return on Equity (ttm)
-26.74%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.57M
Diluted EPS (ttm)
-1.89
Balance Sheet and Cash Flow
Total Cash (mrq)
7.65M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.59M